Autopsy report · NCT05094206

CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

“Treated four patients: 2 at a dose of 1x10\^6 cells/kg and 2 ad at dose of 2.5x10\^6 cells/kg. All four patients had no in-vivo expansion and no meaningful response to therapy. At this point per FDA guidance we will not be treating more patients.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 1 year 7 months before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Medical College of Wisconsin

Sponsor type

University, hospital or other

Conditions

B-cell Non Hodgkin Lymphoma; B-cell Chronic Lymphocytic Leukemia

Interventions

0.75x10^6 cells/kg CAR20.19.22 cells; 1x10^6 cells/kg CAR20.19.22 cells; 2.5x10^6 cells/kg CAR20.19.22 cells; 5x10^6 cells/kg CAR20.19.22 cells; Dose expansion: The maximum tolerated dose of CAR20.19.22 cells

Participants

4

Sites

1

Countries

United States

Trials that died the same way

• METHOD - Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease
  “Due to the slow recruitment process and the progress of newer cell types we decided to stop the trial after the phase 1 (after 10 patients included)” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.